Biomarkers, dementia, and public health

Annals of the New York Academy of Sciences

Volumn 1180, Issue , 2009, Pages 11-19

  Wright, C F ^a   Hall, A ^a   Matthews, F E ^b   Brayne, C ^c  

^a PHG FOUNDATION   (United Kingdom)

^b MRC BIOSTATISTICS UNIT   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Alzheimer's disease; Biomarkers; Dementia; Prevention; Public health; Screening

Indexed keywords

APOLIPOPROTEIN E; BIOLOGICAL MARKER;

ALZHEIMER DISEASE; CONFERENCE PAPER; COST OF ILLNESS; DEMENTIA; DIFFUSE LEWY BODY DISEASE; DISEASE MARKER; FRONTOTEMPORAL DEMENTIA; HUMAN; LEGAL ASPECT; LONG TERM CARE; MEDICAL ETHICS; MULTIINFARCT DEMENTIA; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIMARY MEDICAL CARE; PUBLIC HEALTH; QUALITY OF LIFE; RISK FACTOR; SCREENING; SOCIAL ASPECT; TREATMENT RESPONSE;

BIOLOGICAL MARKERS; DEMENTIA; HUMANS; PUBLIC HEALTH PRACTICE;

EID: 70449449417     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.04942.x     Document Type: Conference Paper

References (42)

1. Wilson, J.M. & Y.G. Jungner. 1968. [Principles and practice of mass screening for disease]. Bol. Oficina Sanit. Panam. 65: 281-393.
2. Zimmern, R.L. & M. Kroese. 2007. The evaluation of genetic tests. J. Public Health (Oxf.) 29: 246-250.
3. Wimo, A., L. Jonsson & B. Winblad. 2006. An estimate of the worldwide prevalence and direct costs of dementia in 2003. Dement. Geriatr. Cogn. Disord. 21: 175-181.
4. Knapp, M. & M. Prince. 2009. Dementia UK: The full report. http://www.alzheimers.org.uk/downloads/Dementia-UK-Full-Report.pdf.
5. Matthews, F. & C. Brayne. 2005. The incidence of dementia in England and Wales: Findings from the five identical sites of the MRC CFA Study. PLoSMed. 2: E193.
6. Ferri, C.P., M. Prince, C. Brayne, et al. 2005. Global prevalence of dementia: A Delphi consensus study. Lancet 366: 2112-2117.
7. Hansen, R.A., G. Gartlehner, A.P.Webb, et al. 2008. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: A systematic review and meta-analysis. Clin. Interv. Aging 3: 211-225.
8. Jansson, E.T. 2005. Alzheimer disease is substantially preventable in the United States-review of risk factors, therapy, and the prospects for an expert software system. Med. Hypotheses. 64: 960-967.
9. Bergmann, C. & M. Sano. 2006. Cardiac risk factors and potential treatments in Alzheimer's disease. Neurol. Res. 28: 595-604.
10. Zawia, N.H. & M.R. Basha. 2005. Environmental risk factors and the developmental basis for Alzheimer's disease. Rev. Neurosci. 16: 325-337.
11. Ropacki, S.A. & D.V. Jeste. 2005. Epidemiology of and risk factors for psychosis of Alzheimer's disease: A review of 55 studies published from 1990 to 2003. Am. J. Psychiatry 162: 2022-2030.
12. Winblad, B., G.B. Frisoni, L. Frolich, et al. 2008. Editorial: EADC (European Alzheimer Disease Consortium) Recommendations for future Alzheimer disease research in Europe. J. Nutr. Health Aging 12: 683-684.
13. Lovestone, S. 2006. Biomarkers in Alzheimer's disease. J. Nutr. Health Aging 10: 118-122.
14. Wiltfang, J., P. Lewczuk, P. Riederer, et al. 2005. Consensus paper of the WFSBP Task Force on Biological Markers of Dementia: The role of CSF and blood analysis in the early and differential diagnosis of dementia. World J. Biol. Psychiatry 6: 69-84.
15. Halperin, I., M. Morelli, A.D. Korczyn, et al. 2009. Biomarkers for evaluation of clinical efficacy of multipotential neuroprotective drugs for Alzheimer's and Parkinson's diseases. Neurotherapeutics 6: 128-140.
16. Hampel, H. & Y. Shen. 2009. Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) as a biological candidate marker of Alzheimer's disease. Scand. J. Clin. Lab. Invest. 69: 8-12.
17. 1998. Consensus Report of the Working Group on: "Molecular and biochemical markers of Alzheimer's disease." Neurobiol. Aging 19: 109-116.
18. Bertram, L., C. Lange, K. Mullin, et al. 2008. Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. Am. J. Hum. Genet. 83: 623-632.
19. Roses, A.D. 1996. Apolipoprotein E alleles as risk factors in Alzheimer's disease. Annu. Rev. Med. 47: 387-400.
20. Gureje, O., A. Ogunniyi, O. Baiyewu, et al. 2006. APOE epsilon4 is not associated with Alzheimer's disease in elderly Nigerians. Ann. Neurol. 59: 182-185.
21. Nordberg, A. 2008. Amyloid plaque imaging in vivo: Current achievement and future prospects. Eur. J. Nucl. Med. Mol. Imaging 35(Suppl 1): S46-S50.
22. Hye, A., S. Lynham, M. Thambisetty, et al. 2006. Proteome-based plasma biomarkers for Alzheimer's disease. Brain 129(Pt 11): 3042-3050.
23. Racchi, M., D. Uberti, S. Govoni, et al. 2008. Alzheimer's disease: New diagnostic and therapeutic tools. Immun. Ageing 5: 7.
24. Peskind, E.R., D.W. Tsuang, L.T. Bonner, et al. 2005. Propranolol for disruptive behaviors in nursing home residents with probable or possible Alzheimer disease: A placebo-controlled study. Alzheimer Dis. Assoc. Disord. 19: 23-28.
25. Brayne, C., C. Fox & M. Boustani. 2007. Dementia screening in primary care: Is it time? JAMA 298: 2409-2411.
26. Solomon, P.R. & C.A. Murphy. 2005. Should we screen for Alzheimer's disease? A review of the evidence for and against screening Alzheimer's disease in primary care practice. Geriatrics 60: 26-31.
27. Bertram, L., M.B. McQueen, K. Mullin, et al. 2007. Systematic meta-analyses of Alzheimer disease genetic association studies: The AlzGene database. Nat. Genet. 39: 17-23.
28. Hedera, P. 2001. Ethical principles and pitfalls of genetic testing for dementia. J. Geriatr. Psychiatry Neurol. 14: 213-221.
29. Post, S.G., P.J. Whitehouse, R.H. Binstock, et al. 1997. The clinical introduction of genetic testing for Alzheimer disease. An ethical perspective. JAMA 277: 832-836.
30. UK Advisory Committee on Genetic Testing. 1998. Report on genetic testing for late onset diseases.
31. European Society of Human Genetics PPPC. 2003. Population genetic screening programmes: Technical, social and ethical issues. Eur. J. Hum. Genet. 11: 903-905.
32. American College of Medical Genetics and American Society of Human Genetics Working Group. 1995.
33. On behalf of the European Society for Human Genetics' PPPC. 2003. Population genetic screening programmes: Technical, social and ethical issues. Eur. J. Hum. Genet. 11: 903-905.
34. Hedgecoe, A. 2004. The Politics of Personalised Medicine. Cambridge University Press. Cambridge, UK.
35. American Geriatrics Society Ethics Committee. 2000. Genetic testing for late-onset Alzheimer's disease.
36. Boustani, M., C.M. Callahan, F.W. Unverzagt, et al. 2005. Implementing a screening and diagnosis program for dementia in primary care. J. Gen. Intern.Med. 20: 572-577.
37. UK Mental Capacity Act. 2005.
38. Van DerVorm, A., M.Vernooij, P.Kehoe, et al. 2009. Ethical aspects of research into Alzheimer disease. A European Delphi study focused on genetic and nongenetic research. J. Med. Ethics 35: 140-144.
39. Maclean, A. 2006. Autonomy, consent and persuasion. Eur. J. Health Law 13: 321-338.
40. Parfit, D. 1986. Reasons and Persons.Oxford University Press. Oxford.
41. Jagger, C., R. Matthews, N. Spiers, et al. 2006. Compression or expansion of disability? Forecasting future disability levels under changing patterns of diseases. Wanless Social Care Review Research Report. Leicester Nuffield Research Unit.
42. Kaufman, S.R., J.K. Shim, A.J.Russ. 2004.Revisiting the biomedicalization of aging: Clinical trends and ethical challenges. Gerontologist 44: 731-738.